HLX vs CLOV vs HUM vs CVS

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus -4. 9% for Helix Energy Solutions Group, Inc. (HLX). Humana Inc. (HUM) offers the better valuation at 31. 0x trailing P/E (34. 2x forward), making it the more compelling value choice. Analysts rate Helix Energy Solutions Group, Inc. (HLX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Humana Inc.

(HUM) is the cheapest at 31. 0x versus CVS Health Corporation at 69. 0x. On forward P/E, CVS Health Corporation is actually cheaper at 13. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Helix Energy Solutions Group, Inc.

(HLX) delivered a total return of +90. 0%, compared to -49. 1% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: HUM returned +93. 4% versus CLOV's -66. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

25β versus Clover Health Investments, Corp. 's 1. 36β — meaning CLOV is approximately 453% more volatile than CVS relative to the S&P 500. On balance sheet safety, Helix Energy Solutions Group, Inc. (HLX) carries a lower debt/equity ratio of 40% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus -4. 9% for Helix Energy Solutions Group, Inc. (HLX). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Helix Energy Solutions Group, Inc.

(HLX) is the more profitable company, earning 2. 4% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLX leads at 5. 0% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 13.

0x forward P/E versus 89. 7x for Clover Health Investments, Corp. — 76. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HLX: 39. 3% to $14. 00.

In this comparison, CVS (2.

8% yield), HUM (1. 2% yield) pay a dividend. HLX, CLOV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 8% yield). Both have compounded well over 10 years (CVS: +12. 9%, CLOV: -66. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HLX (Energy) and CLOV (Healthcare) and HUM (Healthcare) and CVS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HLX is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock; CVS is a mid-cap quality compounder stock. HUM, CVS pay a dividend while HLX, CLOV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.